全文获取类型
收费全文 | 1261篇 |
免费 | 117篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 63篇 |
妇产科学 | 18篇 |
基础医学 | 196篇 |
口腔科学 | 46篇 |
临床医学 | 197篇 |
内科学 | 226篇 |
皮肤病学 | 13篇 |
神经病学 | 68篇 |
特种医学 | 254篇 |
外科学 | 98篇 |
综合类 | 25篇 |
预防医学 | 52篇 |
眼科学 | 12篇 |
药学 | 48篇 |
中国医学 | 5篇 |
肿瘤学 | 61篇 |
出版年
2023年 | 9篇 |
2021年 | 12篇 |
2020年 | 12篇 |
2019年 | 12篇 |
2018年 | 30篇 |
2017年 | 18篇 |
2016年 | 23篇 |
2015年 | 24篇 |
2014年 | 31篇 |
2013年 | 33篇 |
2012年 | 41篇 |
2011年 | 34篇 |
2010年 | 47篇 |
2009年 | 65篇 |
2008年 | 48篇 |
2007年 | 35篇 |
2006年 | 28篇 |
2005年 | 22篇 |
2004年 | 25篇 |
2003年 | 36篇 |
2002年 | 20篇 |
2001年 | 24篇 |
2000年 | 22篇 |
1999年 | 23篇 |
1998年 | 56篇 |
1997年 | 57篇 |
1996年 | 70篇 |
1995年 | 51篇 |
1994年 | 47篇 |
1993年 | 50篇 |
1992年 | 18篇 |
1991年 | 16篇 |
1990年 | 21篇 |
1989年 | 37篇 |
1988年 | 34篇 |
1987年 | 35篇 |
1986年 | 36篇 |
1985年 | 29篇 |
1984年 | 18篇 |
1983年 | 10篇 |
1982年 | 22篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1969年 | 4篇 |
1965年 | 3篇 |
排序方式: 共有1385条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
HRAS1-selected, chromosome-mediated transformants vary in phenotype in vitro and tumorigenic potential in vivo 总被引:1,自引:0,他引:1
D J Porteous J E Morten M E Foster G Cranston E Weir-Thompson A Busuttil C J Bobstock C M Steel 《International journal of cancer. Journal international du cancer》1986,38(4):603-612
Transfection of mouse C127 cells with mitotic chromosomes isolated from a human EJ bladder carcinoma cell line gave rise, at high frequency, to foci of transformed cells. Independent, HRAS1-selected chromosome-mediated transformants displayed distinctive cellular morphologies in monolayer culture and colony-forming abilities in low-melting-point agarose. Subcutaneous inoculation of neonatally thymectomized, Ara-C-protected, total-body-irradiated CBA mice was used to compare the tumorigenic potential of each transformant. Significant quantitative and qualitative differences in tumorigenicity were found between transformants which correlated with differences in malignant phenotype observed in vitro. The sensitivity of the tumorigenicity assay is such that rare transformation events can be selected directly in vivo. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.